# Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

> **NCT00958971** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 43 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** TKI258

## Key facts

- **NCT ID:** NCT00958971
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00958971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00958971, "Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00958971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*